Home » Stocks » BXRX

Baudax Bio, Inc. (BXRX)

Stock Price: $0.612 USD -0.024 (-3.71%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $0.610 -0.002 (-0.39%) Jul 26, 7:49 PM
Market Cap 53.60M
Revenue (ttm) 691,000
Net Income (ttm) -52.71M
Shares Out 84.27M
EPS (ttm) -1.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $0.612
Previous Close $0.636
Change ($) -0.024
Change (%) -3.71%
Day's Open 0.624
Day's Range 0.610 - 0.655
Day's Volume 723,265
52-Week Range 0.573 - 3.940

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MALVERN, Pa., July 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today annou...

3 weeks ago - GlobeNewsWire

MALVERN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today anno...

3 weeks ago - GlobeNewsWire

Special meeting to be held virtually on July 13, 2021, at 9:00 a.m. Eastern Time Special meeting to be held virtually on July 13, 2021, at 9:00 a.m. Eastern Time

1 month ago - GlobeNewsWire

MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today anno...

1 month ago - GlobeNewsWire

MALVERN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today anno...

1 month ago - GlobeNewsWire

MALVERN, Pa., May 31, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today annou...

1 month ago - GlobeNewsWire

MALVERN, Pa., May 28, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care setti...

1 month ago - GlobeNewsWire

MALVERN, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care setti...

2 months ago - GlobeNewsWire

MALVERN, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care setti...

2 months ago - GlobeNewsWire

ANJESO ® Demonstrates Continued Progress with Launch; Growth in End-User Unit Sales Increased 40% in Q1 compared to Q4'20

2 months ago - GlobeNewsWire

MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today an...

2 months ago - GlobeNewsWire

Baudax Bio Inc (NASDAQ: BXRX) has announced the online publication of Phase 3b study data highlighting the safety and efficacy of preoperative Anjeso (meloxicam) injection in patients undergoing unilate...

3 months ago - Benzinga

Investors need to pay close attention to Baudax (BXRX) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Annual Meeting to be adjourned solely with respect to Proposal 3 Annual Meeting to be adjourned solely with respect to Proposal 3

3 months ago - GlobeNewsWire

MALVERN, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committe...

3 months ago - GlobeNewsWire

Wall Street recommends purchasing shares of Ra Medical Systems Inc (RMED) and Baudax Bio Inc (NASDAQ:BXRX), which sounds quite unexpected since these two equities have shown poor performance over the pr...

Other stocks mentioned: RMED
4 months ago - GuruFocus

MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President ...

4 months ago - GlobeNewsWire

Company Also Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Company Also Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

4 months ago - GlobeNewsWire

MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President ...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced ...

5 months ago - GlobeNewsWire

MALVERN, Pa., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced ...

5 months ago - GlobeNewsWire

Baudax (BXRX) will provide updates on earnings and revenues when it releases results for fourth-quarter 2020.

5 months ago - Zacks Investment Research

MALVERN, Pa., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the agreement by an accredited ...

6 months ago - GlobeNewsWire

MALVERN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced ...

7 months ago - GlobeNewsWire

Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, the Company'...

7 months ago - GlobeNewsWire

MALVERN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced ...

8 months ago - GlobeNewsWire

ANJESO Found to Provide Superior Pain Relief with Similar or Better Safety Compared to Other Approved IV Non-Opioid Analgesics ANJESO Found to Provide Superior Pain Relief with Similar or Better Safety ...

8 months ago - GlobeNewsWire

Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Baudax Bio, Inc.'s (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

BXRX has been pummeled since the start of the pandemic dropping from the high $7s to the low $1s. In this article, I review the company developments, both negative and positive, that have transpired dur...

8 months ago - Seeking Alpha

MALVERN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it will report third quarte...

8 months ago - GlobeNewsWire

ANJESO ® Launch Underway ; Over 50 Institutions have A dded ANJESO to T heir F ormular ies

9 months ago - GlobeNewsWire

MALVERN, Pa., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committee...

9 months ago - GlobeNewsWire

MALVERN, Pa., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced Gerri Henwood, the Company’s ...

10 months ago - GlobeNewsWire

These penny stocks are company names that won’t break the bank, and boast colossal growth prospects for the 12 months ahead. The post 3 Penny Stocks That Have Triple-Digit Upside Potential appeared fir...

Other stocks mentioned: AMRS, LIFE
10 months ago - InvestorPlace

Baudax Bio: Discounted Despite Long-Term Prospects

10 months ago - Seeking Alpha

MALVERN, Pa., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has been awarded a Gro...

11 months ago - GlobeNewsWire

MALVERN, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Arnold Baskies, M.D. and ...

11 months ago - GlobeNewsWire

Baudax Bio's (BXRX) CEO Gerri Henwood on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Commenced Commercial Launch of ANJESO ® in the U.S.

11 months ago - GlobeNewsWire

Effective October 1, 2020, New Code Expected to Expand Reimbursement Effective October 1, 2020, New Code Expected to Expand Reimbursement

11 months ago - GlobeNewsWire

Virtual Presentation Highlights New ANJESO Clinical Results, Including Safety, Reductions in Opioid Use and Time to Bowel Function Recovery Data When Administered Preoperatively Prior to Colorectal Surg...

11 months ago - GlobeNewsWire

MALVERN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has entered into a Pha...

1 year ago - GlobeNewsWire

ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily D...

1 year ago - GlobeNewsWire

MALVERN, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has closed on a credit...

1 year ago - GlobeNewsWire

Baudax Bio, Inc. (BXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

  ANJESO™ Approved by FDA for the Management of Moderate to Severe Pain; Product Now Available for Ordering and Delivery for Customers

1 year ago - GlobeNewsWire

Virtual Presentation Highlights New ANJESO Health Resource Utilization Data When Administered Preoperatively in Colorectal Surgery as Part of a Multimodal Analgesia Regimen Virtual Presentation Highligh...

1 year ago - GlobeNewsWire

About BXRX

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial,... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
BXRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Baudax Bio stock is "Buy." The 12-month stock price forecast is 3.67, which is an increase of 499.28% from the latest price.

Price Target
$3.67
(499.28% upside)
Analyst Consensus: Buy